Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult win £1.5M innovate UK grant.
Cobra Biologics has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency. Co-winners, Pall Corporation and the Cell and Gene Therapy Catapult will work with Cobra Biologics to investigate continuous manufacturing of adeno-associated virus (AAV) for gene therapy applications.
“In light of the unprecedented clinical successes with a number of ATMPs, we are looking forward to working with Pall and the Cell and Gene Therapy Catapult. Together we will develop innovative in-process analytical techniques and manufacturing approaches based on continuous chromatography platforms, to significantly increase process yields, and, in doing so, make these advanced therapies more accessible to patients,” said Peter Coleman, Chief Executive Officer of Cobra Biologics.
The transition from batch to continuous chromatography will be planned and managed by all parties. The project began in September 2018.
Photo of Peter Coleman, CEO, Cobra Biologics